Welcome Please stand by. We will begin Shortly.

"Big Marijuana – Lessons from Big Tobacco"

Thursday, February 19, 2015 11:00 am PST/ 2:00 pm ET

(90 minutes)



Disclosure

Dr. Kimber Richter, Dr. Sharon Levy, Catherine Saucedo, and Dr. Steven Schroeder have disclosed no financial interest/arrangement or affiliation with any commercial companies who have provided products or services relating to their presentation or commercial support for this continuing medical education activity.

Moderator



Catherine Saucedo

- Deputy Director,
 Smoking Cessation Leadership Center, University of California, San Francisco
- catherine.saucedo@ucsf.edu

Thank you to our funders



Robert Wood Johnson Foundation






Housekeeping

- All participants will be in **listen only mode**.
- Please make sure your speakers are on and adjust the volume accordingly.
- If you do not have speakers, please request the dial-in via the chat box.
- This webinar is being recorded and will be available on SCLC's website, along with the slides.
- Use the chat box to send questions at any time for the presenters.

Introduction by Dr. Schroeder



Steven A. Schroeder, MD


- Director, Smoking Cessation Leadership Center
- Distinguished Professor of Health and Health Care,
 Department of Medicine, UCSF

Today's Speaker



Kimber P. Richter, PhD, MPH Director of UKanQuit and Professor in the Department of Preventive Medicine and Public Health at the University of Kansas Medical Center

Today's Speaker



Sharon J. Levy, MD, MPH

Assistant Professor of Pediatrics at Harvard Medical School and the Director of the Adolescent Substance Abuse Program in the Division of Developmental Medicine at Boston Children's Hospital

Big Marijuana – Lessons From Big Tobacco

Kimber Richter, PhD, MPH Sharon Levy, MD, MPH

GUTC CONTRACTOR The NEW ENGLAND JOURNAL of MEDICINE

Perspective

Big Marijuana — Lessons from **Big Tobacco**

Kimber P. Richter, Ph.D., M.P.H., and Sharon Levy, M.D., M.P.H.

The United States is divided over the legalization J of marijuana. Arguments in favor include protection of individual rights, elimination of criminal sentencing for minor offenses, collection of tax reve-

nue, and elimination of the black went further, authorizing the remarket. Counterarguments include the possible escalation of use, adverse mental and physical health effects, and potential medical and social costs.

taken to reduce harsh and racially biased sentencing. There is growing support in Congress to eliminate federal mandatory minimums for drug offenses, and 19 states have either decriminalized or eliminated jail time for possession of small amounts of marijuana. Furthermore, 21 states and the District of Columbia have legalized the medical use of signed to protect consumers, mariju an a.

tail sale of marijuana and opening the door to a legal marijuana industry. Given the lessons learned from the 20th-century rise of another legal addictive Some steps have already been substance, tobacco, we believe that such an industry could transform marijuana and its effects on public health. Like tobacco, marijuana harms health and is addictive; unlike alcohol, both tobacco and marijuana came of age after the Industrial Revolution. And although the United States has, since tobacco's rise, adopted regulatory structures dethey do not apply to marijuana, Washington State and Colorado in part because marijuana use

and sales remain illegal under federal law, Colorado and Washington are developing regulatory infrastructures to fill this gap, but the goals and potential effectiveness of their proposed regulations are unclear. No evidence exists regarding which regulations might minimize population harm from marijuana. The marijuana industry's trajectory could therefore repeat tobacco's.

In its current form, smoked marijuana is less deadly than tobacco. Although case-control studies have found increased mortality associated with heavy mariuana use - attributable to vehicle crashes from driving while high, suicide, respiratory cancers, and brain cancers4 - the nonfatal adverse effects of marijuana use are much more prevalent. These include respiratory damage, cardiovascular disease, impaired cognitive development,

1

Legalizing Marjuana

Pros

- Individual rights
- Eliminating harsh sentencing
- Tax revenues
- Eliminate black markets

Cons

- Health/mental health harms
- Developmental harms
- Misguided treatment
- Social costs

Marijuana is a Moving Target

In 1970, 1 joint =.5 g weight=5 mg

10 joints (heavy daily use) 50 mg


	THC %
1970's	1.08
1980's	2.83
1990's	3.76
2000's	5.73





Learning Lessons From Tobacco







Spit to Cigarettes

- 1880s <1% of tobacco consumed as cigarettes
- New mild strains developed
- Flue curing made tobacco inhalable
- Bonsack Machine could produce 70k cigs/day
- American Tobacco Co. created monopoly
- Tobacco tax financed Civil & Spanish-American wars
- 1900 1 out of 3 tobacco users smoked cigs

Cigarettes for All

- WWI spread use of cigarettes
- 1922-cigarette smokers outnumbered other tobacco users
- 1949 45% of Americans smoked
- 1950s introduced asbestos-filtered cigarettes
- 50s-60s introduced free-basing with ammonia to promote rapid absorption
- 1970s Virginia Slims/Silvas marketed to women

Policy Efforts

- 1900 3 states banned cigarette sales due to Lucy Gaston campaign against youth tobacco use
- 1965 Labeling act
- 1967 FCC ruling
- 1970 Hearings on advertising
- 1990s Liability claims
- 1998 Master settlement agreement
- 2009 US FDA has regulatory oversight over tobacco products


Kluger, Richard. (1996). Ashes to Ashes. New York: Knopf; Ford, Barry. (1994). Smokescreen. Perth, Australia: Halcyon; http://www.stateoftobaccocontrol.org/tobacco-timeline.html

Tobacco Industry Lobbied Against Meaningful Regulation

- 1906 Food and Drug Act
- 1966 Fair Labeling and Packaging Act
- 1970 Controlled Substance Act
- 1972 Consumer Product Safety Act
- 1976 Toxic Substances Act

Kluger, Richard. (1996). Ashes to Ashes. New York: Knopf

Product, Marketing, Lobbying









How's That Working for Us?

"The Public Health Service feels the weight of the evidence is increasingly pointing in one direction: that excessive smoking is one of the causative factors in lung cancer."

Surgeon General Leroy E. Burney July 12, <u>1957</u>

Report of the Advisory Committee to the Surgeon General of the Public Health Service . Smoking – Health. 1964.



The benefits of electronic cigarettes

- NO cancer causing chemicals
- Healthy alternative to the real thing
- Smoke in smoke free areas
- Cheaper alternative
- No cancer causing tabacco
- ☑ No fire therefore not a fire risk
- No passive smoke to those around
- No bitter aftertaste
- Read More...

Marijuana


Cannabinoids in Marijuana

- delta-9-tetrahydrocannabinol (THC)
- delta-8-tetrahydrocannabinol
- cannabidiol
- cannabinol
- cannabichromene
- cannabigerol
- More than 100 in total

Source: Mechoulam R, Hanus L, The cannabinoid system from the point of view of a chemist. In *Marijuana and Madness.* ed. Castle, Murray. Cambridge University Press, 2004


Delta-9tetrahydrocannabinol

Anandamide




THC vs. Anandamide

- Anandamide blocks the release of a number of neurotransmitters thereby reducing neuronal activity.
- THC has a MUCH STRONGER, LONGER effect than anandamide on brain cells.
- THC interferes with anandamide function hampering the innate homeostatic system in chronic marijuana users





The neuron's "volume control": dials down neuron activity when too strong ers

Signal direction for neurotransmitters



Source: Kraft, U. Scientific American Mind, 2006, p. 62-65





- THC reduces hippocampal neuron activation
- With chronic THC exposure, neurons are gradually lost due to continual suppression
- THC users have <u>smaller</u> hippocampuses, and poorer memory

Source: Iversen L. How cannabis works in the brain. In *Marijuana and Madness*. Ed. Castle & Murray, 2004. Oxford University Press.

Persistent cannabis users show neuropsychological decline from childhood to midlife


Madeline H. Meier^{a,b,1}, Avshalom Caspi^{a,b,c,d,e}, Antony Ambler^{e,f}, HonaLee Harrington^{b,c,d}, Renate Houts^{b,c,d}, Richard S. E. Keefe^d, Kay McDonald^f, Aimee Ward^f, Richie Poulton^f, and Terrie E. Moffitt^{a,b,c,d,e}

^aDuke Transdisciplinary Prevention Research Center, Center for Child and Family Policy, ^bDepartment of Psychology and Neuroscience, and ^cInstitute for Genome Sciences and Policy, Duke University, Durham, NC 27708; ^dDepartment of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710; ^eSocial, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, King's College London, London SE5 8AF, United Kingdom; and ^fDunedin Multidisciplinary Health and Development Research Unit, Department of Preventive and Social Medicine, School of Medicine, University of Otago, Dunedin 9054, New Zealand


Source: Meier et al. Proceedings of the National Academy of Sciences. 2012. Available at: www.pnas.org/cgi/doi/10.1073/pnas.1206820109

PNAS

The Dunedin Study N=1,037



Source: Meier et al. PNAS, 2012




Association between cannabis use and schizoaffective disorder


	# Exposure	# Cases	HR Crude	HR adjusted*
Never used cannabis	39, 978	47	1	1
Ever used cannabis	5,109	12	2.1 (1.1-3.8)	0.8 (.2-2.9)
>50 times	855	7	7.5 (3.4- 16.7)	7.4 (1.0 – 54.3)

* Adjustments for: prior personality disorders at conscription, IQ, disturbed behavior in childhood, social adjustment, risky use of alcohol, smoking, early adulthood socioeconomic position, use of other drugs, brought up in a city. The category "Ever used cannabis" includes all individuals who reported cannabis use, including those who reported ">50 times".


Griffith-Lendering, Addiction, 108(4), 733-740. Manrique-GarciaBMC Psychiatry, 12, 112.



Patient with Schizophrenia




Age at First Use and Later Risk of Marijuana Disorder



Source: Hingson RW, Heeren T, Winter MR. Age at drinking onset and alcohol dependence. *Arch Pediatr Adolesc Med.* 2006;160:739-746.

"Medical Marijuana" v. Cannabinoids

"Medical Marijuana"	Cannabinoids
Plant species	Pharmaceutical product
Decided by popular vote in 18 states	Regulated by the FDA
Delivered by smoking or orally	Delivered by inhalation or orally
"Recommendation" by physician	Standard prescribing procedures
Efficacy poorly defined	Efficacy carefully studied



"Charlotte's Web"



Cannabinoids have pharmaceutical potential, but



Marijuana is not medicine



1. Limited evidence of therapeutic efficacy of medical marijuana

Condition	Level of Evidence
Chemotherapy induced Nausea and Vomiting in Adults	Modest evidence ¹
Chronic Pain	Insufficient evidence ²
HIV/Aids and Anorexia associated with Aids	Insufficient evidence ³
Neurological Problems	Insufficient evidence ⁴

*Not one single study has ever included children

Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. *Pharmacotherapy*. 2013;33(2):195–209..
 Martín-Sánchez E, Furukawa TA, Taylor J, Martin JLR. Systematic review and meta-analysis of cannabis treatment for chronic pain.
 Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. *Cochrane database Syst. Rev.*.
 Koppel BS, Brust JCM, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2014;82(17):1556–63.

2. No standardization of product



2. No standardization of product





2. No standardization of product





3. Dispensaries are NOT pharmacies



Dispensaries: the Colorado experience

"Medical Marijuana" was approved in Colorado in 2001.

The Colorado Medical Marijuana Code creating a **commercial** scheme for "dispensaries" went into effect July 1, 2010

Colorado Medical Marijuana Dispensaries

The Colorado Medical Marijuana Dispensaries app displays the locations of dispensaries that provide medical marijuana to qualified patients in the state of Colorado.



SUMMIT WELLNESS HIGHEST GRADE MEDICINE IN COLORADO INCLUDING 35+ STRAINS, BEST EDIBLES IN TOWN, Herbal Wellness Inc. Superstore **MULTIPLE FLAVORS OF TINCTURES, HASH,** HAND ROLLED JOINTS, CLONES House Strains Top Shelf Matter Masil MadiPhatz. Hinda Haze **Crystel Churk** Farmary Drives FREE RAFFLE Buiblingum Lenge Sour Biesel Hash Trufflery/ Toffler Super Limber Have G Butz Butter Sage: ENTRY TO WIN 1 OF 3 PRI Moul Wowie Peranut Butter Master Kuth DRAMING WILL RECEIVE CHIEFE OF INCHES Winda Hale 4 Blackberry Kush Rubpe DRIVER SUPPER VAPORER Der s Hain Exil Mint Instee Turomies ZND DRAWING WILL RECEIVE A STORE OF Millenium Sweet Tooth anna Canela Dil **Orach** Blue Chuire tack Of Gummles NO BRANING NEL RECEIVE A \$50 STORE OF PILINE CONTRACT. FREE MEDICINE FOR ANYONE MAKES US THEIR CAREGIN 2117 LARIMER ST **DENVER. CO 80205** **TWO BLOCKS FROM** 3.5 grams of COORS FIELD 720-407-8112 BLUEBERRY with this cause **MONDAY-FRIDAY 10** SATURDAY 10-5 SUNDAY 11-4 New Summer Hours: WALK INS WELCOM Monday - Saturday BAM-BPM 12-5 on Sundays WWW.SUMMIT-WELLNESS

Littlet, its sensity used staring the stig, MDRA deviation strains preasity affects describes and being. Parar shoks attendary senatasis, a rear-structurelitier, adult acts in the case spaceto, mand, and search function.

> PROCE: But used during non-active litters during the day or exercise, NO By a sense of calm or servicity. These strates are used to relate and its relation administe appendie and online intrancular pressure.



For Renewals From Any Doctor

Cultivation Licenses Available

Closes

Cinily 99

Big Bring

Sour Power

Biosbarry

White Widow

Arrageddon Skurk

Line Green Shark


Buttergum

Anarchy Skanil

For New Patient Evaluations Walk-ins Welcome Tel: 323 944 0437

Applications for marijuana card in CO

2001-2008: 6,369 applications 2009-2012: 161,690



JAMA Pediatrics. 2013;167(7):630-633. doi:10.1001/jamapediatrics.2013.140

Condition	# Patients	% Patients
HIV/AIDS	495	1%
Glaucoma	837	1%
Cachexia	1,137	1%
Seizures	1,329	2%
Cancer	2,217	3%
Severe Nausea	9,998	12%
Muscle Spasms	14,255	17%
Severe Pain	76,887	94%

*CO, 2012. Patients may report >1 debilitating condition.

http://www.cdphe.state.co.us/hs/Medicalmarijuana/

Condition	# Patients	% Patients
HIV/AIDS	495	1%
Glaucoma	837	1%
Cachexia	1,137	1%
Seizures	1,329	2%
Cancer	2,217	3%
Severe Nausea	9,998	12%
Muscle Spasms	14,255	17%
Severe Pain	76,887	94%

*CO, 2012. Patients may report >1 debilitating condition.


http://www.cdphe.state.co.us/hs/Medicalmarijuana/

Reported Condition	Total # Patients 1/31/2009	Total # Patients 1/31/2012
Cachexia, cancer, HIV/AIDS, glaucoma, severe nausea, seizures, muscle spasms	2829	31,258 11X increase
Just "severe pain"	1559	46,619 30X increase

http://www.cdphe.state.co.us/hs/Medicalmarijuana/

Age of Patients Using


Total Patients = 127,816



http://www.cdphe.state.co.us/hs/Medicalmarijuana/


Graph courtesy of Christian Thurstone, MD

Teen Past Month MJ Use National v. Colorado




SAMHSA.gov, National Survey on Drug use and Health

Drug-related School Suspensions and Explusions in Colorado



Source of marijuana for adolescents entering SUD treatment program



Thurstone, C., Lieberman, S.A., Schmiege, S.J. Medical marijuana diversion and associated problems in adolescent substance treatment. Drug and Alcohol Dependence; (2011) 118:489–492

Decriminalization and Legalization

<u>Decriminalization</u>: marijuana remains illegal but punishment for possession and use are reduced to noncriminal offences.

Intent: Discourage use, prohibit distribution.

<u>Legalization</u>: marijuana becomes a legal product that adults can buy and use and companies can sell and market

Intent: Eliminate black market, regulate sales, collect taxes.

Impact of Legalization: Colorado

- The city Denver has the highest rate of teen marijuana use in the country.
- The rate of car crashes with drivers testing positive for marijuana in Colorado have almost tripled between January and April 2014.

http://www.learnaboutsam.org/. Colorado Report Card 4/20. 2014





Changing Product

The THC content of U.S. marijuana has more than **doubled** over the past 40 years.

Decade	Avg THC %
1970's	1.08
1980's	2.83
1990's	3.76
2000's	5.73

• Edible products are available for people who do not want to smoke.





- Producers are manufacturing strains that they *claim* are less addictive or less harmful to mental health.
- New vaporizer delivery systems now yield an equivalent THC dose to smoked marijuana with less throat irritation.



- Pure cannabis oils (100%) THC are now available.
- "Because they're so potent, you don't need a large amount to get high."
 - The Wire, May 15, 2013
- "Reduces exposure to other toxins."



High potency THC

• Increases risk of psychosis Br J Psychiatry. 2009 Dec;195(6):488-91

• Decreases age of onset psychosis Schizophr Bull. 2014 Nov;40(6):1509-17.

• Impairs "creative thinking" Psychopharmacology (Berl). 2014 Oct 7. **Exclusive:** Bethenny Frankel Planning to Launch "Skinnygirl Marijuana", a Strain of Pot That Won't Cause the Munchies!

CELEBRITY NEWS JAN. 15, 2015 AT 12:20PM BY SIERRA MARQUINA





An insider close to the Skinnygirl cocktails creator, tells **Us**, "She read about how profitable the cannabis industry is and wants to get in on that."

-US Magazine online

Conclusions

- Marijuana is harmful for the adolescent brain
- Marijuana is not medicine. Administering cannabinoids via marijuana is a disservice to those who receive it.
- The impact of legalization is unknown. The history of the tobacco industry should make us cautious about allowing a marijuana industry, regulated by the free market, to develop.

Questions and Answers



Submit questions via the chat box

Contact SCLC for technical assistance



FREE CME/CEUs of up to 1.5 credits are available to all attendees of this live session. Instructions will be emailed after the webinar.

SCLC has added two new recorded webinars, offering FREE CE credit, on our website: "Tobacco Kills: Intervention and Policy Solutions in Addiction Treatment" and "Where's the Justice? Tobacco Use and the Incarcerated". Please refer to the SCLC website for details: <u>http://smokingcessationleadership.ucsf.edu/webinars/cme</u>

Contact SCLC for technical assistance

Visit us online

http://smokingcessationleadership.ucsf.edu

Call us toll-free

1-877-509-3786



CME/CEU Statement

Accreditation:

The University of California, San Francisco (UCSF) School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

UCSF designates this live activity for a maximum of *1.5 AMA PRA Category 1 CreditsTM*. Physicians should claim only the credit commensurate with the extent of their participation in the webinar activity.

Nurse Practitioners and Registered Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts *AMA PRA Category 1 CreditTM* issued by organizations accredited by the ACCME.

Physician Assistants: The National Commission on Certification of Physician Assistants (NCCPA) states that the *AMA PRA Category 1 Credits*TM are acceptable for continuing medical education requirements for recertification.

California Pharmacists: The California Board of Pharmacy accepts as continuing professional education those courses that meet the standard of relevance to pharmacy practice and have been approved for *AMA PRA category 1 creditTM*. If you are a pharmacist in another state, you should check with your state board for approval of this credit.

Social Workers: This course meets the qualifications for 1.5 hours of continuing education credit for MFTs and/or LCSWs as required by the California Board of Behavioral Sciences. If you a social worker in another state, you should check with your state board for approval of this credit.